Table 1.
Patient demographics.
| Age range (years): | 53-87 (m 70.4). |
|---|---|
| Gleason score range | 6-9, 47% of pts had a GS of 9 |
| PSA range | 1.8-4476.8 (m 430.4) |
| Soft tissue metastasis (pts) | 33.3% |
| Bone metastasis (pts) | 86.6% |
| Castrate resistance disease (pts) | 93.3% |
| High-risk hormonal sensitive disease (pts) | 6.6% |
| Prior treatments (pts) | |
| 1.Docetaxel | 26.6% |
| 2.Enzalutamide | 66.6% |
| 3.Abiraterone | 53.3% |
| 4.Oral anti-androgens | 66.6% |
| 5.ADT | 100% |
| ALK-P range | 16-2605 IU/L (m 255.8) |
| LDH range | 133-623 IU/L (m 267) |
| HGB range | 9.3-16.6 g/dl (m 13.2) |
Abbreviations: ADT: androgen deprivation therapy; ALK-P: alkaline phosphatase; HGB: hemoglobin; LDH: lactate dehydrogenase; m: mean; pts: patients.